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Abstract. The transcription factor Ets-1 is known to be involved 
in a broad variety of cellular functions such as cell prolifera-
tion, migration, invasion, apoptosis and angiogenesis. In nearly 
all these reports, the full-length Ets-1 (p51) is commonly 
considered to be the active form and the role of the Ets-1ΔVII 
splice variant (p42) has not been addressed. Therefore, we 
studied the functional effects of p42 Ets-1 in comparison to 
p51 Ets-1 expression in a well-characterized mouse fibroblast 
cell line. Furthermore, the specific role of Ets-1 was evaluated 
using mouse fibroblasts with a reduced Ets-1 expression caused 
by RNAi and compared to fibroblasts with a binding inhibi-
tion of the whole ETS transcription factor family by stably 
overexpressing the ETS DNA binding domain as trans-
dominant-negative mutant. Our results demonstrate that p42 
Ets-1 has quite different functions and target genes compared 
to p51 Ets-1 (e.g. TIMP-4, MMP-3, MMP-9, MMP-13). In 
some cases (e.g. in cytokine expression) p42 Ets-1 is a func-
tional transcription factor which acts in the same manner as a 
transdominant-negative approach. 
Introduction
Ets-1, the founding member of the ETS family, is expressed in 
endothelial cells during physiological and, more importantly, 
pathological conditions such as tumour vascularization and is 
proposed to play a role in angiogenesis (1-7). We previously 
showed that ets-1 is expressed in stromal capillary endothelials 
and fibroblasts of several human carcinomas, in correlation 
with tumour vascularization and invasion (6-12). Ets-1 is also 
expressed in epithelial carcinoma cells, though less frequently 
than in stromal cells (6,7,9,10,13). 
All members of the ETS transcription factor family share 
a specific DNA-binding domain composed of ~80 amino acids 
(ETS domain) (14) which mediates transactivation or repres-
sion of numerous target genes (15-22). Because of the high 
conserved ETS domain the ETS transcription factor members 
have overlapping specificities (23) and it is possible to block 
the effects of the whole ETS family by expressing an Ets 
transdominant-negative mutant in the cell (24).
In the full-length isoform of the Ets-1 transcription factor 
(p51 Ets-1), two inhibitory regions located on either side of the 
ETS domain associate together and regulate p51 Ets-1 affinity 
for DNA. In the absence of DNA, the N-terminal part of this 
region, coded by exon VII, interacts with the ETS domain and 
with the C-terminal region to create an autoinhibited conforma-
tion. When p51 Ets-1 is bound to DNA, the inhibitory α helix 1 is 
unfolded and the inhibitory module unpacked, this status corre-
lates with a higher affinity for DNA (25-27). In p51 Ets-1, the 
domain encoded by exon VII contains four serine residues that 
are phosphorylated upon Ca2+ activation (28). This phosphory-
lation inhibits DNA binding by reinforcing the autoinhibition 
(28,29). Thus, the domain encoded by exon VII plays a central 
role in p51 Ets-1 as it is directly involved in the regulation of 
DNA binding and is target of second messenger pathways.
In human, mouse and rat, an Ets-1 variant that arises from 
the splicing of exon VII has been identified (p42 Ets-1) (30-33). 
This variant displays specific properties that are not shared by 
the full-length protein; it misses the essential serine residues 
and is not subject to Ca2+-dependent phosphorylation and inhi-
bition of DNA (28,29,34), moreover, p42 Ets-1 induces colon 
cancer cell apoptosis (35) and overexpression of caspase-1/ICE 
in these cells while p51 Ets-1 does not (36). The role of p42 
Ets-1 has not been extensively studied and several fundamental 
questions concerning its function and target genes remain even 
if it has been shown that p42 Ets-1 is a functional transcription 
factor with a quite different DNA recognition capacity from 
that of p51 Ets-1 (30).
In the present work we have studied the functional effects 
of p42 Ets-1 in comparison to p51 Ets-1 expression in mouse 
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fibroblasts. Furthermore, the specific role of Ets-1 was evalu-
ated using mouse fibroblasts with a reduced Ets-1 expression 
caused by RNAi and compared to fibroblasts with a binding 
inhibition of the whole ETS transcription factor family by 
stably over-expressing the ETS-DNA binding domain as 
transdominant-negative mutant.
Materials and methods
Plasmid construction. The mouse ets-1 coding sequence was 
amplified by PCR using mRNA derived from mouse fibro-
blasts with the deoxyoligonucleotides 5'-ATGAAGGCGGC 
CGTCGATCTCAAGCCG-3' and 5'-CCATGACAAGTCAG 
CATCCGGCTTTACATC-3'. The amplified fragment was 
inserted into the pcDNA3.1 vector (Invitrogen) in sense and 
anti-sense orientation resulting in pcDNA3.1m-ets-1 and 
pcDNA3.1m-ets-1 inverse, respectively. The DNA binding 
domain of ets-1 was amplified by PCR and the amplified frag-
ment was inserted into the pEGFP-C vector (Clontech). The 
plasmid coding for ets-1 splice variant ΔVII was kindly provided 
by F. Soncin (30). All constructs were verified by sequencing.
Cell culture and stable transfections. NIH3T3 cells were 
cultured in Dulbecco's modified Eagle's medium (DMEM, 
Invitrogen) supplemented with antibiotics and 10% heat-
inactivated fetal calf serum (FCS, Invitrogen). The plasmids 
were transfected into the cells by the calcium phosphate 
method (37,38). Twenty-four hours after transfection, selection 
was started using 400 µg/ml G418 (Life Technologies).
Preparation of nuclear extract and Western blotting. Nuclear 
extracts were prepared as described previously (39). Briefly, 
5x106 cells were washed twice in 10-ml ice-cold phosphate-
buffered saline (PBS, Invitrogen), resuspended in 500 µl 
buffer A [10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM 
KCl, 0.5 mM DTT (pH 7.9)] with protease inhibitor cocktail 
(Roche Diagnostics) and incubated on ice for 15 min. NP-40 
was added to a final concentration of 0.5%, and the cells were 
vortexed for 10 sec. The nuclei were collected by centrifuga-
tion (6500 x g for 20 min) and resuspended in 150 µl buffer 
C [20 mM HEPES (pH 7.9), 1.5 mM MgCl2, 420 mM NaCl, 
0.2 mM EDTA, 25% (v/v) glycerol) with protease inhibitors. 
The nuclear suspension was stirred vigorously on ice for 
30 min. The sample was centrifuged at 13000 x g for 10 min, 
and aliquots of the supernatant were frozen immediately on 
dry ice. The protein concentration was determined by Bradford 
assay (BioRad) prior to Western blotting. Total protein (12.5 µg) 
was analysed by 10% SDS-polyacrylamide gel electrophoresis 
and transferred onto nitrocellulose (Bio-Rad). After blocking 
with 5% non-fat dry milk in PBS (Invitrogen) for 2 h at room 
temperature, filters were incubated in TBS-T (50 mM Tris, 
150 mM NaCl, 0.1% Tween-20, pH 7.5) and with anti-Ets-1 
rabbit polyclonal serum (1:1000; Transduction Laboratories), 
then with the horseradish peroxidase-conjugated secondary 
antibody (1:5000; Amersham Biosciences). Antibodies were 
detected using ECL reagents (Amersham Biosciences). 
Luciferase reporter gene assay. The TIMP-4/pGL2 plasmid 
(3 µg per well) bearing the luciferase gene under the control 
of the TIMP-4 promoter was transfected into the cells 
(1x106 cells per 35-mm well) as described above, together with 
3 µg of pCH110 (Amersham Pharmacia) normalization vector. 
Luciferase and β-galactosidase activity were measured using a 
luminometer (Berthold) according to manufacturer's instruc-
tions (Promega and Tropix, respectively).
Soft agar assay. Cells (105 cells in DMEM, 20% FCS) were 
mixed with an equal volume of 0.8% agarose (FMC BioProducts) 
and poured onto a bed of 1.4% agarose in culture plates. The 
plates were fed every 3 days with 2 ml of DMEM containing 
10% FCS. The plates were observed for colony formation.
Invasion assay. Invasion assays were performed in Matrigel 
Chambers (Becton-Dickinson) containing polyethylene 
membranes with 8-µm pore size coated with basement 
membrane (Matrigel, Becton-Dickinson). NIH3T3 cells were 
harvested by trypsinization, resuspended in DMEM at a density 
of 5x104 cells/ml and 2.5x104 cells were plated in the upper 
compartment of the chamber. After incubation at 37˚C for 22 h 
filters were removed. Cells adhering to the lower surface were 
fixed, stained with Hemacolor® (Merck) and counted.
Cytokine determination. Cell density was adjusted to 
1000 cells/ml in DMEM supplemented with 0.5% penicillin-
streptomycin and 0.5% FCS. Part of the adjusted experimental 
culture (1 ml) was added to each well of a 24-well-plate 
(1000 cells/well). The plates were incubated at 37˚C with 5% 
CO2 in a humidified atmosphere for 24 h. Supernatants from 
wells of the same cell line were pooled and centrifuged at 
4000 rpm for 10 min at room temperature. Clear supernatants 
were used for the cytokine determination. Measurement of 
cytokines [IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, 
IL-12 (p40), IL-12 (p70), IL-17, G-CSF, GM-CSF, IFN-γ, 
KC, MIP-1α, RANTES and TNF-α] were performed with the 
BIO-PLEX-System (Bio-Rad) according to the manufacturer's 
instructions.
RNA isolation and cDNA synthesis. Total cellular RNA was 
extracted from cell monolayers by the RNeasy kit (Qiagen). 
Generation of cDNAs by reverse transcriptase was performed 
in 10-µl reaction volume containing 2 µg of total cellular RNA, 
1 µl of dNTPs (10 mM), 1 µl of oligo(dT)12-18 primer (10 mM), 
and RNAse-free water. After incubation at 65˚C for 5 min the 
reaction mixture was placed on ice for 1 min. Then 2 µl of 10X 
RT buffer (Invitrogen), 4 µl MgCl2 (25 mM), 2 µl of 0.1 M 
DTT, and 1 µl RNAseOut™ recombinant RNAse inhibitor 
(Invitrogen) was added. After incubation at 42˚C for 2 min 1 
µl of Superscript II reverse transciptase (50 U/µl; Invitrogen) 
was added for the transcription at 42˚C for 1 h. Inactivation of 
the enzyme was performed at 70˚C for 15 min. In the last step 
RNA was removed by addition of 1 µl RNAseH and incubated 
at 37˚C for 20 min.
PCR. For analysis of gene expression polymerase chain reaction 
(PCR) amplifications were performed using GeneAmp PCR 
System 9700 (Applied Biosystems). All primers were synthe-
sised by TIB MolBiol and the primer sequences are summarized 
in Table I. PCR amplification of cDNA was performed in a 
reaction containing 2.5 µl of 10X polymerase buffer, 1.5 mM 
MgCl2, 0.2 mM each desoxynucleoside triphosphate, 25 pmol 
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5' primer and 25 pmol 3' primer, 0.1 µl (0.5U) Taq DNA poly-
merase, 0.5 µl cDNA template and sterile RNAse-free water to 
a total volume of 25 µl. All PCR reagents were from Invitrogen.
First of all amplification of a house-keeping gene, the 
constitutively expressed ribosomal protein L13A (rpL13A) (40), 
was undertaken to monitor the quality of the RNA extraction, 
the cDNA synthesis and to ensure that equivalent amounts of 
cDNA were used in all PCR amplifications. All PCR reactions 
were preceded by a denaturation step at 94˚C for 1 min followed 
by 25 cycles of denaturation, annealing and extension; PCR 
conditions for the different cDNAs are shown in Table II. Every 
PCR reaction was finished by a final elongation step at 72˚C for 
10 min. All PCR products were analysed by separation on a 2% 
agarose gel stained with ethidium bromide.
Immunohistochemistry. Cells grown in 1 cm2 culture chambers 
(Nunc) were rinsed once with PBS (Invitrogen), twice with 70% 
ethanol and fixed in a mixture of ice cold methanol and ethanol 
[1:2 (v:v)] at 4˚C for 20 min. After washing twice with PBS 
(Invitrogen) cells were stained with antibodies directed against 
integrin-β2; 1:200 dilution (41), Santa Cruz Biotechnology. 
The cells were incubated with the primary antibody at 37˚C 
for 60 min. Detection of the primary antibody was carried out 
by using the LSAB-peroxidase-system (Dako) according to 
the manufacturer's instructions.
Results
Ets-1 expression and activity. The well characterized NIH3T3 
cell line was used to monitor the effects of Ets-1 and the role 
of the two different splice variants in fibroblasts. Four stable 
NIH3T3 cell lines were established following transfection 
with either an Ets-1 p51, an Ets-1 p51-anti-sense, an Ets-1 
p42 or an Ets-1-DNA binding domain (Ets-1-DB) expression 
Table I. Primer used for RT-PCR.
Gene Forward primer Reverse primer
RPL-13 A 5'-TACGCTGTGAAGGCATCAAC-'3 5'-CACCATCCGCTTTTTCTTGT-'3
Ets-1 5'-CGATCTCAAGCCGACTCTCA-'3 5'-GAAGCTGGGCTCTGAGAACTC-'3
Ets-1 (exonVII) 5'-CCCTCTCCAGACAGACACCTTG-'3 5'-GCCACGGCTCAGTTTCTCAT-'3 
TIMP-1 5'-CATGGAAAGCCTCTGTGGATATG-'3 5'-AAGCTGCAGGCACTGATGTG-'3
TIMP-2 5'-CCAGAAGAAGAGCCTGAACCA-'3 5'-GTCCATCCAGAGGCACTCATC-'3
TIMP-3 5'-GGCCTCAATTACCGCTACCA-'3 5'-CTGATAGCCAGGGTACCCAAAA-'3
TIMP-4 5'-TGCAGAGGGAGAGCCTGAA-'3 5'-GGTACCCATAGAGCTTCCG-'3
MMP-2 5'-GTACTGGGTCTATTCTGCTAG-'3 5'-CACTTCATTGTATCTCCAG-'3
MMP-3 5'-ACGAGGGCACGAGGAGCTAGC-'3 5'-GGGTCAAATTCCAACTGAGAAG-'3
MMP-9 5'-GTTCCCACTTACTATGGAAAC-'3 5'-CGTGCTCCGTGTAGAGTCTC-'3
MMP-13 5'-GAATGGTTATGACATTCTGGA-'3 5'-GATACTGTATTCAAACTGTATGG-'3
Cadherin-11 5'-TTGGCTCTGAACAGCTGAAA-'3 5'-CCCAAGTCAGCTCACAGTCA-'3
Fibulin 5 5'-GTGAACGAGTGCGAAACTGA-'3 5'-CTGGCAGCTTCGGTTATCAT-'3
Table II. PCR conditions used for amplification with 25 cycles of denaturation, annealing and extension.
 Denaturation Annealing Extension
rpL13A 94˚C for 30 sec 66˚C for 30 sec 72˚C for 30 sec
ets-1 94˚C for 30 sec 65˚C for 30 sec 72˚C for 60 sec
ets-1 (ExonVII) 94˚C for 30 sec 65˚C for 30 sec 72˚C for 60 sec
timp 1 94˚C for 30 sec 60˚C for 30 sec 72˚C for 30 sec
timp 2 94˚C for 30 sec 60˚C for 30 sec 72˚C for 30 sec
timp 3 94˚C for 30 sec 60˚C for 30 sec 72˚C for 30 sec
timp 4 94˚C for 30 sec 60˚C for 30 sec 72˚C for 30 sec
mmp 2 94˚C for 30 sec 57˚C for 30 sec 72˚C for 30 sec
mmp 3 94˚C for 30 sec 65˚C for 30 sec 72˚C for 30 sec
mmp 9 94˚C for 30 sec 64˚C for 30 sec 72˚C for 30 sec
mmp 13 94˚C for 30 sec 59˚C for 30 sec 72˚C for 30 sec
Cadherin-11 94˚C for 30 sec 56˚C for 30 sec 72˚C for 30 sec
Fibulin 5 94˚C for 30 sec 56˚C for 30 sec 72˚C for 30 sec
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vector. Full-length Ets-1-overexpressing (3T3-Ets-1) and 
-under expressing (3T3-inverse) cell lines as well as Ets-1 p42 
(3T3-Ets-1ΔVII) and Ets-1-DB overexpressing cell lines were 
selected from the pooled population of transfected cells, in 
order to avoid clonal variations. The resulted cell lines were 
first analysed for Ets-1 transcripts by RT-PCR and compared 
to wild-type NIH3T3 cells (Fig. 1A). As expected for the 
ubiquitously expressed transcription factor, Ets-1 transcripts 
were found in NIH3T3 wild-type cells but only the full-length 
transcript was detected. In the 3T3-Ets-1 cell line a higher 
expression level of full-length Ets-1 and in the 3T3-Ets-1ΔVII 
cell line transcripts coding for the splice variant Ets-1ΔVII 
in addition to the full-length transcripts were found. In the 
Ets-1-DB overexpressing cell line Ets-1 full-length transcripts 
can be detected in the same range as in wild-type cells, because 
endogenous Ets-1 level is not affected on the RNA level by the 
Ets-1-DB expression. In contrast a significantly reduced level 
of Ets-1 transcripts was found in the 3T3-inverse cell line as 
expected for this RNAi-based strategy.
The established cell lines and the parental cells were also 
analysed on the protein level by Western blotting with an 
ETS-1-specific antibody (Fig. 1B). An upregulation of Ets-1 
full-length protein (p51; lane 3) and of Ets-1 splice-variant 
lacking exon VII (p42; lane 2) in the stable-transfected NIH3T3 
cell lines was found. The inverted Ets-1 sequence (lane 4) effec-
tively abrogates both p51 and p42 expression. It is evident that 
the mock-transfected cells (lane 1) are identical with NIH3T3 
wild-type cells (lane 5). The expression of Ets-1-DB in the 
established cell line could not be demonstrated by Western 
blotting due to the fact that the antibody recognized an epitope 
outside the Ets-1-DB DNA sequence.
In the next step we addressed the question of protein 
localisation in the cells. For this purpose the different tags 
fused to the transgenes are used for immunohistochemical 
analysis (Fig. 2). The nuclear expression of the overexpressed 
p51 and p42 Ets-1 was visualized by using antibodies against 
the V5 and the HA epitope, respectively. For demonstrating 
the expression of the Ets-1-DB the fluorescence of the fused 
EGFP was used by fluorescence microscopy. These obser-
vations suggest that the properties of the established 3T3 
cell lines corresponded to the strategy that was adopted to 
produce them.
In order to evaluate the effect of the different Ets-1 
expression levels and splice variants in fibroblasts cellular 
behaviour was accessed in different assays. The proliferation 
rates of 3T3-Ets-1, 3T3-Ets-1ΔVII, 3T3-inverse and wild-type 
NIH3T3 cells were found to be comparable (Fig. 3). In the 
case of 3T3 Ets-1-DB increased cell growth was observed; 
Figure 1. RT-PCR analysis (A) and Western blotting (B) showing expression 
of the different Ets-1 constructs. (A) Expression of transcripts was analysed 
with specific primers for Ets-1 and Ets-1ΔVII in NIH3T3 cells (lane 1), 3T3-
Ets-1 cells (lane 2), 3T3-Ets-1ΔVII cells (lane 3), Ets-1-DB overexpressing 
cells (lane 4) and 3T3-inverse cells (lane 5). The negative control (C) for 
any PCR is shown at the end of every line. The house-keeping gene rpL-13A 
was amplified in order to monitor RNA quality and cDNA synthesis and to 
ensure that equivalent amount of cDNA were used in all PCR amplifications. 
Fragment sizes were evaluated with a PCR-marker (M); gene specific prod-
ucts are 251-bp for rpL-13A, 536-bp for Ets-1 and 268-bp for Ets-1ΔVII. (B) 
Western blotting showing expression of full-length Ets-1 protein (p51) and of 
Ets-1 splice-variant lacking exon VII (p42) in NIH3T3 mock-transfected cells 
(lane 1), 3T3-Ets-1ΔVII cells (lane 2), 3T3-Ets-1 cells (lane 3), 3T3-inverse 
cells (lane 4) and wild-type NIH3T3 cells (lane 5).
Figure 2. Localisation of the different Ets-1 constructs in the cells. Locali-
sation and expression of Ets-1 full-length (B) and Ets-1ΔVII (D) was analysed 
in 3T3-Ets-1 and 3T3-Ets-1ΔVII cells, respectively, by detection of the fused 
tag (100-fold magnification) in comparison to controls with wild-type NIH3T3 
cells (A and C). Localisation and expression of Ets-1-DB-EGFP fusion protein 
(E, transmitted light; F, fluorescence light) in Ets-1-DB overexpressing cells 
was analysed by immunofluorescence (20-fold magnification).
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after 48 h the cells were confluent and after 120 h they were 
detached (Fig. 3). 
Next we compared the invasive activity of the different cell 
lines in a Matrigel invasion assay. NIH3T3 and 3T3 Ets-1-DB 
cells had a comparable invasive behavior, while 3T3-Ets-1 
cells showed a slight increase in invasive migration through the 
Matrigel (Fig. 4). In contrast 3T3-Ets-1ΔVII and 3T3-inverse 
cells showed a decreased invasive behaviour. The invasive 
migration was decreased >25% in 3T3-inverse cells and ~20% 
in 3T3-Ets-1ΔVII cells compared to 3T3-Ets-1 cells. These 
results showing that p51 Ets-1 overexpression increase the 
migrating and invasive properties of 3T3 cells, suggested that 
full-length Ets-1 had a transforming effect on these cells. In 
contrast p42 Ets-1 overexpression decreased the migration and 
invasive properties of 3T3 cells and the effects are comparable 
with a reduction of full-length Ets-1 expression in 3T3 cells.
Migration and motility of cells requires a coordinated swap 
between cell detachment and attachment, we therefore exam-
ined the influence of Ets-1 expression on the attachment of 3T3 
cells. As illustrated in Fig. 5, differences in attachment of the 
different cell lines were observed 2.5 h after seeding the cells 
into the wells. Nearly 90% of the NIH3T3 cells and 92% of the 
3T3-Ets-1 cells had attached to the plastic surface while >98% 
of 3T3-Ets-1ΔVII and 3T3 Ets-1-DB cells were detected after 
the same time, but <87% of the 3T3-inverse cells had attached 
to the plastic surface. This suggests that expression of p42 Ets-1 
as well as the transdominant negative approach favours slightly 
3T3 cell adhesion. 
In order to investigate further this point, we analyzed the 
influence of Ets-1 on contact inhibition and clonal growth of 
3T3 cells using soft-agar assay. As shown in Fig. 6 3T3-Ets-1 
cells showed the strongest capability for colony formation of the 
3T3 cell lines studied. Notably 3T3 Ets-1-DB and 3T3-invers 
cells were unable to grow in an anchorage-independent way. 
Compared to NIH3T3 cells the 3T3-Ets-1 cells have a slightly 
increased and the 3T3 Ets-1ΔVII cells a slightly reduced 
growing capacity.
The observed differences in migration, clonogenicity and 
anchorage-independent growth between the different cell lines 
prompted us to analyse the effect of Ets-1 expression on the 
expression levels of several integrin receptors. Ets-1 expression 
did not affect the levels of integrin-β4 (CD104), integrin-α6 
(CD49f), integrin-α3β1 (CD49c) or integrin-β3 (CD61) (data 
not shown). However, we observed a strong induction of 
integrin-β2 (CD18) expression in 3T3-Ets-1 and 3T3-Ets-1ΔVII 
particularly when compared to NIH3T3 cells while expression 
was reduced in 3T3 Ets-1-DB and undetectable in 3T3-inverse 
cells (Fig. 7).
Another reason for the observed differences in migration, 
clonogenicity and attachment between the different cell lines 
could be based on the cytokine expression. Therefore, we 
addressed the expression pattern of cytokines in the different 
fibroblast cell lines (Fig. 8). IL-1β expression was comparable 
in wild-type 3T3 and 3T3-Ets-1 cells. The IL-1β expression 
was increased 5- to 6-fold in 3T3-Ets-1ΔVII and 3T3 Ets-1-DB 
cells. IL-10, IFN-γ and IL-12 (p70) expression were nearly 
the same in all cell lines. TNF-α expression was slightly 
increased in 3T3-Ets-1 cells compared to the wild-type cells 
and significantly induced in 3T3-Ets-1ΔVII and 3T3 Ets-1-DB 
cells. IL-1α was only detected in 3T3 Ets-1-DB cells at a very 
low level. Again the expression of MIP-1α was the same in 
Figure 3. Cell proliferation rates. Proliferation rates of the different cell lines 
were determined by a modified MTT-assay during 120 h. The mean value of 
three independent experiments is shown.
Figure 4. Invasive behaviour of the different cell lines. Cells were plated in 
the upper compartment of Matrigel Chambers containing polyethylene mem-
branes with 8-mm pore size coated with basement membrane. After incubation 
at 37˚C for 22 h, the filters were removed and the cells adhering to the lower 
surface were fixed, stained and counted. The mean value of three independent 
experiments is shown.
Figure 5. Attachment of the different cell lines. Cells (106 per well) were 
seeded into 10 cm2 culture wells and incubated at 37˚C. After 2.5 h, living 
cells in the supernatants were counted. The mean value of four independent 
experiments is shown.
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wild-type 3T3 and 3T3-Ets-1 cells and strong reduced in 
3T3-Ets-1ΔVII and 3T3 Ets-1-DB cells. The cytokines IL-2, 
IL-3, IL-4, IL-5, IL-6, IL-12 (p40), IL-17, G-CSF, GM-CSF, 
KC and RANTES were not expressed in any of the cell lines 
(data not shown).
Finally the expression levels of further potential Ets-1 target 
genes were addressed by RT-PCR analysis. Results of the PCR 
amplifications are shown in Fig. 9 and the quantification is 
summarized in Table III. The mRNA of the house-keeping 
gene rpL13A was amplified in all probes in the same range. 
Since it has been well established that genes of tissue inhibi-
tors of metalloproteinases (TIMPs) are also among Ets-1 
target genes we examined the expression of TIMP-1-4 in the 
different fibroblast cell lines. The expression of TIMP-1 was 
increased in all cell lines compared to NIH3T3 cells. TIMP-2 
expression was increased in 3T3-Ets-1, 3T3-Ets-1ΔVII and 
particularly in 3T3 Ets-1-DB cells. TIMP-3 expression was 
Figure 6. Anchorage-independent growth of the different cell lines (soft-agar assay). Cells (105 in DMEM, 20% FCS) were mixed with an equal volume of 0.8% 
agarose and poured onto a bed of 1.4% agarose in culture plates. The culture medium was changed every 3 days and colony formation monitored (day 47, 
43.75-fold magnification).
Figure 7. Expression of integrin β2 in the different cell lines. Higher expression of integrin β2 (CD18) correlates with Ets-1 full-length and Ets-1 ΔVII expres-
sion. The negative control (no Ab) was incubated under the same conditions omitting primary antibody (50-fold magnification).
Figure 8. Cytokine expression profile of the different cell lines. From each cell 
line 1000 cells were incubated in wells of a 24-well plate for 24 h. Supernatants 
from 6 wells of the same cell line were pooled and centrifuged at 4000 rpm 
for 10 min at room temperature. The amount of cytokines in this clear super-
natant was determined with the BIO-PLEX-system. The mean value of two 
independent experiments is shown.
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comparable in all 3T3 cell lines. The most striking difference 
between the cell lines concerned TIMP-4 expression. TIMP-4 
was only expressed in the 3T3-Ets-1ΔVII cells. 
Metalloproteinases (MMPs) are among the best char-
acterized Ets-1 target genes and therefore we examined 
the expression of MMP-2, MMP-3, MMP-9 and MMP-13. 
MMP-2 expression was slightly increased in 3T3-Ets-1 
cells. MMP-3 and MMP-13 expression was only detected in 
3T3-Ets-1ΔVII cells whereas all other cell lines are nega-
tive for MMP-3 as well as MMP-13. MMP 9 expression was 
strongly induced in 3T3-Ets-1 cells and slightly in 3T3-Ets-1 
ΔVII cells. Cadherin-11 is slightly decreased in 3T3 Ets-1-DB 
Table III. Quantification of the PCR products by densitometric measurement.a
Gen NIH3T3 3T3-Ets-1 3T3-Ets-1Δ VII 3T3-Ets-1-DB 3T3-inverse
RPL13A 1.0 1.0 1.0 1.0 1.0
Ets-1 1.0 1.5 1.2 1.0 0.8
Ets-1 ∆7 0.0 0.0 1.7 0.0 0.0
TIMP-1 1.0 1.6 1.3 1.6 1.6
TIMP-2 1.0 1.1 1.2 1.2 0.7
TIMP-3 1.0 1.1 1.2 0.8 0.7
TIMP-4 0.0 0.0 1.5 0.0 0.0
MMP-2 1.0 1.5 1.2 1.1 1.1
MMP-3 0.0 0.0 1.2 0.0 0.0
MMP-9 1.0 1.5 1.3 1.0 0.9
MMP-13 0.0 1.0 1.3 0.0 0.0
Cadherin-11 1.0 1.1 1.1 0.8 0.7
Fibulin-5 1.0 1.2 1.0 0.6 1.3
aThe expression rate in NIH3T3 cells was set as one and the expression rate in the other cell lines was related to the control cells. If a gene was 
not expressed in NIH3T3 cells the induction rate was related to the background.
Figure 9. RT-PCR analysis of known Ets-1 target genes in the different cell lines. Determination of tissue inhibitors of metallomatrix proteinases and protease 
expression in NIH3T3 cells (lane 1), 3T3-Ets-1 cells (lane 2), 3T3-Ets-1ΔVII cells (lane 3), Ets-1-DB overexpressing cells (lane 4) and 3T3-inverse cells 
(lane 5). The negative control (C) for any PCR is shown at the end of every line. Fragment sizes were evaluated with a PCR-marker (M); gene specific products 
are 251-bp for rpL13A, 108-bp for TIMP-1, 122-bp for TIMP-2, 135-bp for TIMP-3, 130-bp for TIMP-4, 166-bp for MMP-2, 280-bp for MMP-3, 188-bp for 
MMP-9, 295-bp for MMP-13, 274-bp for cadherin-11 and 239-bp for fibulin 5.
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and 3T3-inverse cells, whereas fibulin 5 is slightly decreased in 
3T3 Ets-1-DB cells.
The surprising finding that TIMP-4 is only expressed in 
the 3T3-Ets-1ΔVII cells was further evaluated with a reporter 
gene assay (Fig. 10). Therefore the different cell lines were 
transiently co-transfected with a plasmid coding for luciferase 
under the control of TIMP-4 promoter and a plasmid coding 
for β-galactosidase. The highest TIMP-4 promoter activity 
was observed in 3T3-Ets-1ΔVII cells; in comparison to all 
other cell lines the differences were statistically significant at 
P<0.005. In 3T3-inverse and 3T3 Ets-1-DB cells the TIMP-4 
promoter activity was significant reduced compared to the 
NIH3T3 cells.
Discussion
Ets-1 expression has been associated with several aspects 
of embryonic development, including vasculogenesis and 
angiogenesis (5,42-44), epithelial to mesenchymal transition 
(44,45) and implantation (2). In the adult, ets-1 is expressed 
in the granulation tissue during wound healing, but also in 
endothelial cells of solid tumours (7,46) and in the tissue 
stroma in reaction to tumours (6,47). Ets-1 is also expressed 
in hematopoietic cells (45) during the lymphoid differentiation 
(48) and seems to play an important role in T-cell survival (49) 
and the establishment of NK cells (50). In all these reports, the 
full-length Ets-1 was commonly considered to be the active 
form and the role of the Ets-1ΔVII splice variant has not been 
addressed in detail. Therefore we examined here the role of 
Ets-1ΔVII splice variant in comparison to the full-length Ets-1 
in mouse fibroblasts in regard to known Ets-1 target genes. Our 
results demonstrate that p42 Ets-1 has quite different functions 
and target genes compared to p51 Ets-1 (e.g. TIMP-4, MMP-3, 
MMP-9, MMP-13). In some case (e.g. in cytokine expression) 
p42 Ets-1 is a functional transcription factor which acts in the 
same manner as a transdominant negative approach. Therefore 
we postulate that p42 Ets-1 binds to the same core DNA recog-
nition sites as p51 Ets-1 and thereby the Ets-1ΔVII splice variant 
prevents the binding of full length Ets-1. Previously it has been 
demonstrated by Lionneton et al that the mouse Ets-1ΔVII 
splice variant beside the ETS binding site also recognized a 
site similar to the Spi-1/PU.1 DNA recognition site (30). It is 
well known that the effects of transcription factors onto their 
target genes, activation as well as repression, is mediated by 
co-factors and intermediates. In the case of Ets-1 the splice 
variant p42 could have a different set of co-factors compared 
to the full-length protein or the co-factors are unable to bind to 
the ΔVII splice variant. 
Previously it has been demonstrated that Ets-1 ΔVII splice 
variant escapes calcium-dependent inactivation and shows 
much higher DNA-binding activity than full-length Ets-1 
(28,29). It has been suggested that Ets-1 ΔVII splice variant 
compete with or compensate the function of the full-length 
transcript even when expression levels are lower than that of 
p51.
Recently we studied the effects of Ets-1 in mouse embryonal 
fibroblasts by comparing wild-type fibroblasts with fibroblasts 
derived from ets-1 knock-out mouse (51). The Ets-1 ΔVII splice 
variant was not detected in the wild-type or in the Ets-1-/- 
fibroblasts (51). We found that basal full-length Ets-1 levels 
are necessary for a fast induction of MMP-2, -3, -9 and -13 
by bFGF (51). In contrast to the results obtained with mouse 
embryonal fibroblasts we found MMP-3 and MMP-13 expres-
sion only in NIH3T3 cells expressing the Ets-1 ΔVII splice 
variant. This discrepancy could be most probably explained 
by the differences between primary cells and an established 
cell line. Furthermore it is possible that during embryogenesis 
and bFGF stimulation another set of co-factors is expressed 
resulting in different MMP expression pattern compared to 
the MMP expression in an immortalised cell line. In mouse 
embryonal fibroblasts the basal full-length Ets-1 levels are 
also found to be necessary for a maintenance of bFGF-induced 
expression of tissue inhibitors of metalloproteinases 1, 2 and 3 
known to not only inhibit but also to participate in activation 
of certain pro-MMPs (51). Of special interest we found no 
TIMP-4 expression in these embryonal fibroblasts (51). So it 
seems that TIMP-4 expression is directly linked to the Ets-1 
ΔVII splice variant. Furthermore, we observed in a reporter 
gene assay the strongest transcriptional activity of the TIMP-4 
promoter in 3T3-Ets-1ΔVII cells.
In regard to the fact that overexpression of TIMP-4 has been 
shown to inhibit growth and invasion of tumour cells (52-54) the 
Ets-1 ΔVII splice variant could exert at least to a certain degree 
the observed increase in cell attachment, the decreased capacity 
for anchorage-independent growth and the reduced invasive 
behaviour through the activation of TIMP-4 expression. 
The cytokine IL-1β is known to induce the expression of 
adhesions molecules on various cell types (55). Therefore the 
increased expression of IL-1β detected in 3T3-Ets-1 ΔVII and 
3T3-Ets-1-DB cells could also result in the observed increase 
in cell attachment. In agreement with the increased cell 
attachment is also the high expression level of integrin β2 in 
3T3-Ets-1 ΔVII cells, but in 3T3-Ets-1-DB cells the integrin β2 
expression was very low. This finding suggests that other adhe-
sion molecules must have a higher impact on the cell attachment 
behaviour. Moreover, it is well established that integrin β2 
besides mediating interactions between adhesions molecules 
is involved in triggering intracellular signalling (56). Therefore 
the expression level of integrin β2 is not necessarily correlated 
with the extent of adhesion.
Figure 10. TIMP-4 driven luciferase expression in the different cell lines. In 
order to evaluate the transcriptional activity in regard to TIMP-4 expression in 
the different cell lines, a plasmid bearing the luciferase gene under the control 
of the TIMP-4 promoter was transiently transfected into the cells together 
with the pCH110 normalization vector. Luciferase and β-galactosidase 
activity were measured using a luminometer. The normalized luciferase 
activity measured in NIH3T3 cells was set as 100%. The mean value of two 
independent experiments and measurements is shown.
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In conclusion, our results suggest that the Ets-1ΔVII splice 
variant has different functions in comparison to the full-length 
Ets-1 in mouse fibroblasts. The highest differences between the 
full-length Ets-1 and the Ets-1ΔVII splice variant are found in 
the cytokine expression profile as well as in MMP  and TIMP 
expression patterns. 
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